President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?

The article argues that Trump's Most-Favored-Nation drug pricing policy could pressure U.S. pharmaceutical profits, but Johnson & Johnson and Roche should cope better because of their diversified businesses. Johnson & Johnson is guided to $100.8 billion in revenue this year, up 7%, while Roche is leaning on diagnostics and a pipeline that could deliver up to 19 new medicines by decade-end. Roche also agreed to buy SAGA Diagnostics for up to $595 million to bolster its molecular residual disease testing franchise.

Analysis

The real market implication is not that drug-price reform crushes the entire healthcare complex, but that it widens the gap between “pure-play pricing leverage” and “portfolio insulation.” Firms with meaningful exposure to devices, diagnostics, or other non-reimbursed revenue streams can absorb Medicare/MFN pressure without a full multiple reset, because the earnings mix shifts away from the channel most exposed to policy. That makes JNJ and Roche more of a relative-safe-haven trade than a classic absolute long — especially if policymakers keep targeting the highest-spend categories where volume can still be managed but margin per unit compresses.

The second-order effect is that pricing pressure can actually accelerate capital allocation into adjacent businesses that are less politically sensitive and more procedurally sticky. For JNJ, robotic surgery is less about near-term share capture versus incumbents and more about optionality on a long-duration installed-base build; if clearance arrives, the market will likely underwrite a multi-year hardware/service annuity stream rather than a one-off device launch. For Roche, diagnostics is the cleaner hedge: MRD testing has a reimbursement profile tied to oncology workflows and treatment decisions, so it may prove more resilient than therapeutics if drug price caps spill into sentiment across the sector.

The contrarian point is that the selloff risk may be overstated for diversified large caps and understated for mid-cap pharma with concentrated U.S. exposure and limited non-drug offsets. The real losers are likely companies reliant on a handful of Medicare-heavy products, where even a modest haircut can cascade into lower R&D optionality, slower pipeline spend, and valuation compression over 6-18 months. If policy implementation stays narrow and reimbursement changes are gradual, the market could quickly rotate back to cash-rich healthcare franchises with durable capital returns.

Key Decisions for Investors

• Long JNJ versus a basket of U.S.-centric pharma with concentrated reimbursement exposure; 6-12 month horizon, using JNJ’s diversification and dividend support as downside buffer while capturing relative multiple resilience.
• Initiate a pair trade: long JNJ / short a concentrated pharma name with heavy Medicare exposure; target a 5-10% spread over 3-6 months if MFN rhetoric intensifies and investors continue de-risking pricing-sensitive names.
• Long Roche on a 6-18 month horizon as a policy hedge inside healthcare; the diagnostics mix plus pipeline optionality should make it less rate-sensitive to U.S. pricing headlines than pure pharma peers.
• If JNJ pulls back on policy headlines, buy staged exposure rather than chasing strength; the setup is better on red days because the market tends to over-discount broad policy risk before earnings prove the offset from devices.
• Avoid chasing small/mid-cap biotech with single-asset U.S. revenue dependence until the rulemaking path is clearer; the skew is unfavorable because downside from reimbursement compression can hit faster than any pipeline catalyst can re-rate the stock.